Hurkmans, Daan P <br/><br/>
Tumor mutational load, CD8  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  May 2020 
 - 771-777 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1432-0851 
<br/><br/><label>Standard No.: </label>10.1007/s00262-020-02506-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents, Immunological--pharmacology<br/>B7-H1 Antigen--analysis<br/>Biomarkers, Tumor--analysis<br/>Biopsy<br/>CD8-Positive T-Lymphocytes--immunology<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Clinical Decision-Making--methods<br/>Disease Progression<br/>Female<br/>Follow-Up Studies<br/>Histocompatibility Antigens Class I--analysis<br/>Humans<br/>Lung--pathology<br/>Lung Neoplasms--drug therapy<br/>Lymphocytes, Tumor-Infiltrating--immunology<br/>Male<br/>Middle Aged<br/>Mutation Rate<br/>Nivolumab--pharmacology<br/>Predictive Value of Tests<br/>Progression-Free Survival<br/>Proof of Concept Study<br/>Prospective Studies<br/>Response Evaluation Criteria in Solid Tumors<br/>Retrospective Studies